Products - Breast cancer | Topic | NICE

Showing 1 product

Date | Title

Advice programme: Evidence summariesRemove ‘Advice programme: Evidence summaries’ filter

Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Product type:
Advice
Programme:
Evidence summary
Published:
13 March 2013